Literature DB >> 854065

Adenosine deaminase inhibition for immunosuppression.

M M Chassin, M A Chirigos, D G Johns, R H Adamson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 854065

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Combined immunodeficiency and inborn errors of purine metabolism.

Authors:  H J Meuwissen; B Pollara
Journal:  Blut       Date:  1978-10-13

2.  Role of adenosine deaminase in activation of macrophages.

Authors:  K Yagawa; J Okamura
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

3.  Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.

Authors:  R F Kefford; R M Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 4.  Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression.

Authors:  R I Glazer
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity.

Authors:  T S Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

6.  The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  J F Smyth; R M Paine; A L Jackman; K R Harrap; M M Chassin; R H Adamson; D G Johns
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Inhibition of lymphocyte response to mitogens by dipyridamole: preliminary findings.

Authors:  I Melamed; A Aviram; A Rubinstein; V Zakuth; G Peresechensky; Z Spirer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Animal model for immune dysfunction associated with adenosine deaminase deficiency.

Authors:  A Tedde; M E Balis; S Ikehara; R Pahwa; R A Good; P P Trotta
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.